Clinical Trials Browser

Colorectal Neoplasms

NCT05886257 2023-06-02

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT03843853 2022-07-25

Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Phase 2 Withdrawn

CNS

Glioblastoma, Glioma

NCT03836157 2019-06-27

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Phase 2 Withdrawn

Gynecologic

Endometrial Neoplasms

NCT03161041 2018-11-14

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study

Phase 2 Withdrawn

Gynecologic

Peritoneal Neoplasms

NCT01426074 2018-08-21

DCE-MRI PET Bevacizumab Study in Rectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Rectal Cancer Patients

NCT00577109 2018-07-31

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT00388700 2018-02-14

A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT01788280 2018-02-07

Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Phase 2 Withdrawn

CNS

Glioblastoma

NCT01782976 2018-01-19

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Phase 2 Withdrawn

CNS

Glioblastoma, Recurrence

NCT00600210 2017-08-23

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Phase 2 Withdrawn

Gynecologic

Uterine Cervical Neoplasms

NCT00408772 2017-06-09

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT02413853 2017-04-17

PRIMIER

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT01270438 2017-04-04

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00964704 2016-11-02

A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT00571740 2016-07-06

Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00469976 2015-10-08

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00755157 2015-10-07

Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT00458315 2015-05-08

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Phase 2 Withdrawn

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00469469 2015-04-22

Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

Phase 2 Withdrawn

Endocrine

Adrenocortical Carcinoma

NCT01262859 2014-01-13

Pilot Study for Locally Advanced Head and Neck Cancer

Phase 2 Withdrawn

Head & Neck

Head and Neck Neoplasms

NCT00636298 2013-11-19

Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

Phase 2 Withdrawn

Gastrointestinal

Esophageal Neoplasms

NCT01674738 2013-10-11

SELECT-A

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01293942 2013-06-05

IXO+A in mCRC With Liver-only Metastases

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT01540435 2013-05-29

PERIMAX

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT00118105 2013-01-03

S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT01175291 2011-12-05

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Colorectal Neoplasms

Clinical Trials

INAVO-CRC

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study

DCE-MRI PET Bevacizumab Study in Rectal Cancer

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

PRIMIER

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

Pilot Study for Locally Advanced Head and Neck Cancer

Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

SELECT-A

IXO+A in mCRC With Liver-only Metastases

PERIMAX

S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer